Myriad Genetics Inc
Myriad Genetics Reports Third Quarter 2026 Financial Results;
Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution
Company newsroom
NASDAQ:MYGN
1 releases
Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution